In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 226 to 250 of 404

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]	Technology appraisal guidance	17 July 2024
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]	Technology appraisal guidance	TBC
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]	Technology appraisal guidance	TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]	Technology appraisal guidance	TBC
Non-alcoholic fatty liver disease (NAFLD): assessment and management	NICE guideline	TBC
Non-invasive skin closure devices for surgical incisions (MT775)	Medical technologies guidance	TBC
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]	Technology appraisal guidance	TBC
NY-ESO-1 T-cells for treating synovial sarcoma ID1286	Technology appraisal guidance	TBC
Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]	Technology appraisal guidance	25 June 2025
Obesity: clinical assessment and management (QS update)	Quality standard	TBC
Obesity: prevention and lifestyle management (QS update)	Quality standard	TBC
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]	Technology appraisal guidance	TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]	Technology appraisal guidance	TBC
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]	Technology appraisal guidance	TBC
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]	Technology appraisal guidance	TBC
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]	Highly specialised technology	TBC
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423	Technology appraisal guidance	13 August 2025
Omburtamab for treating relapsed neuroblastoma [ID1664]	Technology appraisal guidance	TBC
One-piece closed bags for adults with a colostomy: Late Stage Assessment	Health technology evaluation	TBC
Optical Coherence Tomography to guide percutaneous coronary intervention	Interventional procedures guidance	TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]	Technology appraisal guidance	TBC

Results per page

10
25
50
All